Sectors
The global semiconductor industry has been experiencing a record amount of IPOs and M&A deals in recent months. A flurry of IPOs and M&As in any industry often serves as a sign of a top in share prices (Chart 1). Chat 1Will Booming Semiconductor IPOs And M&As Mark A Peak In Share Prices? The basis is that IPO and M&A booms usually occur when investor sentiment on that industry is super optimistic, which often coincides with a top in share prices. Does this mean that semiconductor stocks in general, and the ones in Taiwan and Korea in particular, are at their zenith? Our broad judgement is that semi stocks have not reached a secular peak. First, as we argued in a recent Special Report, the semiconductor industry is in a structural uptrend due to the continuing rollout of 5G networks and phones, a wider adoption of data centers, further technological advancements in artificial intelligence, cloud computing, edge computing and smaller nodes for chip manufacturing. Second, it is critical to differentiate a macro call on semiconductors from a bottom-up call on individual stocks. Not all semi companies have rallied in recent years, i.e., there has been great divergence among global semi stocks as shown in Chart 2. Chat 2The Performance Of Semiconductor Stocks Has Varied Greatly Several semiconductor companies – like TSMC, Nvidia and AMD – have achieved technological breakthroughs, putting them in a position to enjoy high order volumes and charge higher prices. Not surprisingly, revenues of these companies have outpaced the industry average by a wide margin (Chart 3). Chat 3Semiconductor Companies' Revenues Have Diverged Others – like Intel and Analog Devices - have posted inferior revenue gains because they have fallen behind technologically or because they are specializing in certain types of semiconductors for which demand and pricing have been lackluster. Chat 4One-Off Surge In Demand For Semis Might Be Over Finally, if the global reflation trade resumes and global stocks continue advancing, as the first post-US election day suggests, there is little reason for global semiconductor stocks to falter at this moment. From the macro perspective, lower interest rates in the long run will support not-so-cheap semiconductor stock valuations. In addition, companies with access to unique technological capabilities will be able to raise their product prices benefiting their profits. That said, there are also several signs that the global semi demand cycle might have entered a period of indigestion: The one-off demand surge for personal computers and gadgets and one-off ramp up of global server shipments due to the pandemic might be drawing to a close (Chart 4, top panel). Digitimes Research has reported that global server shipments are estimated to have slipped 6% sequentially in Q3 from Q2 and are projected to drop another 12% in Q4 (Chart 4, bottom panel). Unlike those in March-April, renewed lockdowns are unlikely to produce another surge in demand for digital equipment and, hence, for semis. Many people and companies have already settled into working from home. In short, as the effect of the one-off demand surge for digital hardware fades, global semi demand will moderate. Semiconductor companies in general, and the ones in Korea and Taiwan in particular, have greatly benefited from China having stockpiled semiconductors in 2019 and 2020 in preparation for US sanctions on Huawei that went into effect on September 15, 2020 (Chart 5). The US supply ban on semiconductors to China for 5G technology will remain in place regardless of the outcome of the US presidential elections. Restrictions on semi sales to China will weigh on certain semi producers. In addition, smartphone sales in China generally, including 5G smartphone sales, have plunged as of late (Chart 6). Chat 5China Has Been Accumulating Semis Inventories Chat 6China: Smartphone Shipments, Including 5G, Are Weak Finally, the PMI new orders sub-index for Taiwan’s electronic industry has rolled over, signaling a slowdown in its growth rate (Chart 7). Similarly, the memory chip revenue indicator has recently rolled over, signaling a potential risk to memory stocks such as Samsung and Hynix which make up the Korean technology index (Chart 8). Chat 7A Moderation In The Taiwanese Semis Industry? Chat 8Proxy for Value Of Memory Chips And Korean Tech Stocks We have been advocating a neutral allocation to both the Korean and Taiwanese stock markets within the EM equity universe. One of our arguments for this strategy has been a potential escalation in the US-China confrontation going into the US elections. However, this risk has not materialized. We are upgrading the Korean bourse to overweight. As to Taiwan, a contested US election and the resulting vacuum of power in the next couple of months might lead to a rise in all types of geopolitical risks around the world. Taiwan could be one of these. We maintain a neutral allocation to the Taiwanese bourse within an EM equity portfolio. Bottom Line: In absolute terms, Korean and Taiwanese equity performance depends on the direction of global stocks. We will discuss the outlook for global and EM stocks in a Strategy Report to be published early next week when there is more clarity on the outcome of the US presidential elections. Within an EM equity universe, we are upgrading Korean stocks from neutral to overweight but keeping Taiwan’s allocation at neutral. Arthur Budaghyan Chief Emerging Markets Strategist arthur@bcaresearch.com Ellen JingYuan He Associate Vice President ellenj@bcaresearch.com Footnotes
Dear client, Instead of our regular Daily Sector Insight, tomorrow we will be sending you our sister’s Geopolitical Strategy service Weekly Report with a post mortem on the US election. On Monday our regular service resumes with a Special Report on SPX earnings penned by my colleague Arseniy Urazov. Kind Regards, Anastasios Today we reiterate our cyclicals over defensives portfolio bent that we instituted in late July. Not only is the slingshot recovery in the ISM manufacturing survey underpinning cyclicals at the expense of defensives (top panel), but also relative debt dynamics will further cement cyclicals’ reign over their defensive peers. The deep cyclicals (tech, industrials, materials and energy) net debt-to-EBITDA ratio has stabilized near 1.5x during the recession on the back of cash flow ails (second panel). In fact, cyclicals have been paying down net debt in absolute terms during the pandemic. In marked contrast, the defensives (health care, consumer staples, utilities and telecom services) net debt-to-EBITDA ratio is hovering near 3x, as these debt saddled sectors have not been able to pay down net debt. Not only is net debt roughly $2tn (bottom panel), but it also comprises 50% of the broad market’s net debt at a time when their market cap weight is close to 30%. Taken together, the relative debt profile clearly favors cyclicals at the expense of defensives. Bottom Line: We continue to recommend a cyclicals versus defensives portfolio bent. For more details, please refer to this Monday’s Weekly Report.
The reopening of the economy remains on track, and this week’s blow out ISM manufacturing PMI print signals that the cyclical part of the economy is firing on all cylinders. Drilling deeper beneath the surface is revealing. First, the utmost important new orders-to-inventories ratio reaccelerated and it corroborates our thesis that the SPX correction is likely drawing to a close (middle panel). Second, the survey’s new orders subcomponent in isolation has vaulted to a level last seen in the aftermath of the 1980s double dip and post the 9/11 induced recessions. The implication is that an earnings driven advance in the SPX is in the cards in 2021, after the election dust settles and investors begin to focus on profit growth anew (bottom panel). Bottom Line: As the election-related uncertainty lifts, we expect the cyclical equity bull market to resume.
The 14th Five-Year Plan has more strategic importance than in the past decade. Spending on national defense, technological self-sufficiency, public welfare and green energy will likely see substantial increases under the guidelines of a strong central government. The Proposal from the Five-Year Plan does not change our cyclical view on Chinese assets. Beyond mid-2021, the differences in sectoral performance will widen. We will likely begin to trim our position in China’s “old economy” stocks in the first half of 2021.
In mid-September, we highlighted the CBOE equity put/call (EPC) ratio that warned investors were complacent. Our goal was to attempt to quantify when the correction would end, and we noted that since the early-2018 “Volmageddon” episode, SPX drawdowns corresponded to higher EPC ratio readings (EPC shown inverted, see chart). As a reminder in the past 10 iterations, the EPC ratio has averaged 0.93 with a 0.86 median, and ranged from 0.74 to 1.28. The price action last Friday finally pushed the EPC ratio to 0.77 signaling that the correction is long in the tooth and some of the speculative fervor was wrung out of the market. Bottom Line: As the election-related uncertainty lifts, we expect the cyclical bull market to resume. Stay tuned.
Your feedback is important to us. Please take our client survey today Highlights Portfolio Strategy An easy Fed, the drubbing in the US dollar, the opening up of the global economy, poor pharma operating metrics and the specter of a “Blue Wave” more than offset the likelihood of a COVID-19 vaccine and oversold technicals, and compel us to cut pharma exposure below benchmark. This downgrade of the heavyweight pharma index also pushes the S&P health care sector down to a neutral position. Recent Changes Downgrade the S&P pharmaceuticals index to underweight, today. Trim the S&P health care sector down to a benchmark allocation, today. Table 1 Feature On the eve of the election, the SPX oscillated violently last week as it became evident that there will be no agreement on a bipartisan fiscal package. Thus, the odds are rising of a mega fiscal package next year irrespective of the election outcome. The longer politicians wait the larger the stimulus bill will end up being. Realistically now a fresh fiscal impulse is pushed out to late-January at the earliest, casting a dark cloud over the current quarter’s economic and profit growth prospects. In mid-October we highlighted that positioning remained stretched in both VIX and S&P 500 e-mini futures, which warned that investors were prematurely betting on subsiding volatility. Similarly, we cautioned that VIX options activity corroborated the stretched positioning message as investors were piling into VIX puts and neglecting to buy any election protection in the form of VIX calls. The final blow came early last week when the equity vol curve inverted with the VIX spiking north of 40 and implying that the SPX would move by +/- 12% in the next 30 days. Given so much fear priced in the VIX, last Thursday we decided to close our election protection in the form of VIX December 16, 2020 expiry futures that we held since our July 27 Special Report we penned with our sister Geopolitical Strategy on the rising odds of a contested US election. Our view remains that the SPX could glide lower into the November election before rallying into year-end courtesy of receding election and fiscal policy uncertainties. Nevertheless, at the risk of getting overly bearish a few offsetting observations are in order. While there is a chance that the VIX will continue to roar as it did early in the year and push the equity vol curve deeper in backwardation, our sense is that the correction that commenced in early September is close to running its course. Historically, Chart 1 shows that the VIX curve inversion is typically short-lived and more often than not serves as a launchpad for the SPX. Chart 1Correction Enters Third Month With regard to market internals, a flurry of M&A activity has propelled the Philly SOX index to all-time highs in absolute terms and to nineteen-year highs versus the SPX. IPO activity has also resumed and the Renaissance IPO exchange trade fund is on a tear breaking out recently to uncharted territory. Moreover, the SPX advance/decline line is also probing all-time highs and signaling increased participation beyond the top 5 tech titans (Chart 2). While the Fed has been a bystander of late – trying to exert some pressure on Congress to pass a fresh stimulus package – and the fiscal circus continues unabated in Washington D.C., both the money supply release and the American Association on Individual Investors confirm that a lot of dry powder remains on the sidelines. The implication is that as election uncertainty recedes then this idle cash courtesy of the sloshing liquidity will make its way through the markets. In other words decreasing cash balances push the SPX higher and vice versa (Chart 3). Chart 2Market Internals: A Few Rays Of Light Chart 3Lots Of Dry Powder Meanwhile, following up from last week’s debt discussion we delve deeper into the non-financial corporate sector’s debt profile. The pandemic has pushed non-financial business debt to an extreme almost on a par with nominal GDP (top panel, Chart 4). The big difference this cycle is that, according to Moody’s, subordinated debt that has defaulted sports a recovery rate in the teens, a far cry from previous recessionary troughs (second panel, Chart 4). The overall junk bond recovery rate is near 25 cents on the dollar plumbing historical lows (a recent Bloomberg article highlighted that COVID-19 has ushered in this “new era of US bankruptcies” with ultra-low recovery rates).1 The risk remains that the default rate will continue to rise (bottom panel, Chart 4): the longer the fiscal stimulus package takes to arrive the higher the bankruptcies will be. Importantly, the deep cyclicals (tech, industrials, materials and energy) net debt-to-EBITDA ratio has crossed above 1.5x during the recession on the back of cash flow ails. In fact cyclicals have been paying down net debt in absolute terms during the pandemic (bottom panel, Chart 5). Chart 4Beware Low Recovery Rates Chart 5Debt Saddled Defensives In marked contrast, the defensives (health care, consumer staples, utilities and telecom services) net debt-to-EBITDA ratio is hovering near 3x, as these debt saddled sectors have not been able to pay down net debt. Not only is net debt roughly $2tn, but it also comprises 50% of the broad market’s net debt at a time when the market cap weight is close to 30% (Chart 5). Taken together, the relative debt profile clearly favors cyclicals at the expense of defensives and we continue to recommend a cyclicals versus defensives portfolio bent. One neglected part of the Baker, Bloom and Davis policy uncertainty has been the trade-related uncertainty. The pandemic has put the trade dispute in the back burner. Moreover, the odds remain high of a Biden win; at the margin, a Democratic President will be less hawkish on trade and will try to deescalate global trade tensions. This backdrop is a de facto positive for cyclicals/defensives, especially given our view of a reopening of the global economy in 2021 (Chart 6). This week we continue to augment the cyclical/defensive bent of our portfolio by taking a defensive sector down a notch. Chart 6Cyclicals Benefit From Dwindling Trade Uncertainty Comatose Big Pharma shares broke down recently and we are compelled to downgrade exposure to underweight on the eve of the US election. While a short term reflex bounce may be in the cards, we would sell that strength as relative share prices are teetering and are on the verge of giving up 25 years of relative returns (top panel, Chart 7). Stiff macro headwinds, tough operating metrics and hawkish political rhetoric more than offset positive COVID-19 vaccine-related news. On the macro front, the Fed’s ZIRP bodes ill for defensive pharma equities. The Fed was uncharacteristically quick this recession to drop rates to the lower zero bound to reflate the economy. As a result, safe haven equities, Big Pharma included, typically trail the broad market as the economy gets out of the ER and into the recovery room (middle & bottom panels, Chart 7). Importantly, relative pharmaceutical profits are highly counter cyclical: they rise with the onset of recession and collapse as the economy stands back on its own two feet. Currently, as the COVID-19 hit to the world economy has transitioned to a V-shaped recovery, the reopening of the economy into the New Year will continue to knock the wind out of relative pharma profitability (global manufacturing PMI shown inverted, middle panel, Chart 8). Chart 7A Tough Pill To Swallow Chart 8Sell The Pharma Counter-Cyclicality Similarly, an appreciating greenback has historically been synonymous with pharma outperformance and vice versa (third panel, Chart 8). Keep in mind, Big Pharma make the lion’s share of their profits domestically further cementing the positive correlation with the US dollar. This local profit sourcing represents one of the main reasons why politicians on both sides of the aisle are after domestic pharma profits (more on this below). Worrisomely and likely tied to the domestic nature of the industry’s profit extraction, the debasing of the US dollar fails to provide any export relief. In fact, exports have been historically positively correlated with the greenback (bottom panel, Chart 8). Pharma prices are on the cusp of contracting. Importantly, President Trump’s late-July executive order “to allow importation of certain prescription drugs from Canada”2 among other provisions is a direct blow to the profit prospects of Big Pharma (second panel, Chart 9). Other operating factors also weigh on pharma earnings. Industry shipments have risen to a level that has marked prior peak growth rates. Any letdown on the demand side coupled with the recent inventory build, will lead to pricing power losses. Tack on accelerating productivity losses despite recovering pharma industrial production and factors are falling into place for a relative profit driven underperformance phase (Chart 9). With regard to the election outcome, a Biden win accompanied by a Senate flip to the Democrats would be the worst possible outcome for the pharmaceutical industry, as we posited in our recent Special Report penned with our sister Geopolitical Strategy services on sector implication of a “Blue Trifecta”, and reiterate today (Chart 10). Chart 9Pricing Power Blues Nevertheless, we are cognizant that definitive news of a COVID-19 vaccine will likely lift Big Pharma, but only temporarily, as cyclical forces will more than offset the positive vaccine news. Finally, with regard to valuations and technicals, pharma is not offering compelling value but rather is a value trap and we would use any reflex rebound to lighten up exposure to this defensive industry (Chart 11). Chart 10Heightened “Blue Sweep” Risk Chart 11Value Trap Netting it all out, an easy Fed, the drubbing in the US dollar, the opening up of the global economy, poor pharma operating metrics and the specter of a “Blue Wave” more than offset the benefits of a COVID-19 vaccine and oversold technicals. Bottom Line: Downgrade the S&P pharmaceuticals index to underweight today. The ticker symbols for the stocks in this index are: BLBG – S5PHARX, JNJ, PFE, MRK, LLY, BMY, ZTS, CTLT, MYL, PRGO. A Few Words On Health Care The Big Phama downgrade to underweight also pushes the S&P health care sector to a benchmark allocation from a previously modest overweight stance. This leaves the S&P medical equipment index as the sole overweight in this defensive sector that enjoys cyclical and structural tailwinds (especially in emerging markets that are instituting the health care safety nets the developed markets already enjoy) more than offsetting the safe haven characteristics that typically overshadow health care outfits (second panel, Chart 12). Moreover, we are putting the S&P health care sector on downgrade alert as we reckon most of the positive profit drivers are already reflected in cycle high relative profit growth figures and are at major risk of deflating if our thesis of a global reopening of the economy takes shape in the New Year. Our relative macro driven EPS growth models corroborate that earnings are at heightened risk of major disappointment next year (Chart 13). Chart 12Stick With Health Equipment Chart 13Put The S&P Health Care Sector On Downgrade Alert Bottom Line: Trim the S&P health care sector to neutral today and also put it on downgrade watch. Anastasios Avgeriou US Equity Strategist anastasios@bcaresearch.com Footnotes 1 https://www.bloomberg.com/news/articles/2020-10-26/bond-defaults-deliver-99-losses-in-new-era-of-u-s-bankruptcies 2 https://www.whitehouse.gov/presidential-actions/executive-order-increasing-drug-importation-lower-prices-american-patients/ Current Recommendations Current Trades Strategic (10-Year) Trade Recommendations Size And Style Views October 26, 2020 Favor small over large caps July 27, 2020 Overweight cyclicals over defensives June 11, 2018 Long the BCA Millennial basket The ticker symbols are: (AAPL, AMZN, UBER, HD, LEN, MSFT, NFLX, SPOT, TSLA, V). January 22, 2018 Favor value over growth
The Fed remains a key player enabling the transition from Washington to fiscally loose Buenos Aires consensus as we outlined in this Monday’s Weekly Report. As fiscal valves open and debt piles rise, the bond market will be the only regulatory mechanism. The implication is that the interplay between future fed funds rate (FFR) expectations and the 10-year US Treasury yield becomes a key variable to monitor. The most recent, and similar to today, period was during the GFC, when the Fed held the FFR near zero from December 2008 until December 2015. In this seven-year period, the interplay between the FFR change expectations and the 10-year US Treasury yield reveals that the sensitivity of interest rates to FFR change expectations stood near 2-to-1; i.e. a 50bps increase in the FFR change expectations would push the 10-year yield 100bps higher and vice versa. Year-to-date, the 10-year US Treasury yield’s sensitivity to FFR change expectations has ranged between 1-to-1 and 2-to-1. Looking ahead post the election, the odds are rising of a mammoth fiscal package, especially if there is a “Blue Sweep” but also potentially in a renewed Trump administration. Under such a backdrop the 10-year US Treasury yield would spike and so will FFR hike expectations. Bottom Line: Any selloff in the bond market will serve as a catalyst for a rotation out of fully valued tech stocks and into deeply undervalued financials (see chart).
Neutral Today, we are removing our downgrade alert from the S&P semiconductors index on the back of an improving macro backdrop. First and foremost, the semi sales cycle is tied to global rates that tend to lead by approximately 18 months. As Central Banks across the globe are committed to remain on the easening path, global semi sales will likely rebound further (middle panel). A revival of chip M&A activity which effectively reduces the supply of stocks does not show any signs of abating, and will continue to underpin semi stocks as premia paid remain elevated (bottom panel). Bottom Line: We remain neutral the S&P semiconductors index, but are removing our downgrade alert. On a related note, our underweight stance in the sister chip equipment index remains intact. Stay tuned.
We take the opportunity presented by this week’s indiscriminate equity market selloff to pocket in gains from our long December 2020 expiry VIX futures recommendation from the joint Special Report on July 27 with our sister Geopolitical Strategy service. The original rationale was to use December 2020 VIX contracts as a hedge versus long equity exposure in case of a contested US presidential election. The recent vol spike pushed returns over 19.5%, assuming no leverage, compelling us to lock in handsome gains this morning. In a real life example, brokers require 50% margin on VIX futures trading implying that the actual return doubles to 39%. While the VIX can continue to rise on the back of next Tuesday’s election uncertainty, we opt to cash out early as others rush in to buy “expensive” protection too little too late. Bottom Line: Remove the election-related hedge and crystallize 19.5% gains in December 2020 expiry VIX futures contracts.